ReviewAdvanced pharmaceutical bulletin2016
Pharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and Development.
Review in Advanced pharmaceutical bulletin, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Fast-Dissolving and Highly Soluble Dasatinib Multicomponent Crystals Efficiently Inhibit Leukemia Cell Viability.ACS omega · 2026Article
- Formulation Strategies to Enhance the Solubility of Poorly Water-Soluble Drugs and Phytochemicals: Current Advances and Challenges.Pharmaceutics · 2026Review
- ML-Driven Pharmaceutical Cocrystal Technology: Advances in Screening, Property Prediction and Applications.AAPS PharmSciTech · 2026Review
- Review
- Pharmaceutical Salts: Comprehensive Insights From Fundamental Chemistry to FDA Approvals (2019-2023).AAPS PharmSciTech · 2025Review
- Highly Soluble Dacarbazine Multicomponent Crystals Less Prone to Photodegradation.Molecular pharmaceutics · 2024Article
- A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Sugars and Polyols of Natural Origin as Carriers for Solubility and Dissolution Enhancement.Pharmaceutics · 2023Review
- Co-Crystallization Approach to Enhance the Stability of Moisture-Sensitive Drugs.Pharmaceutics · 2023Review
- Formation Thermodynamics of Carbamazepine with Benzamide, Para-Hydroxybenzamide and Isonicotinamide Cocrystals: Experimental and Theoretical Study.Pharmaceutics · 2022Article
- First and Second Dissociation Enthalpies in Bi-Component Crystals Consisting of Maleic Acid and L-Phenylalanine.Molecules (Basel, Switzerland) · 2021Article
- Current and potential applications of simultaneous DSC-FTIR microspectroscopy for pharmaceutical analysis.Journal of food and drug analysis · 2021Review
- Hydrophilic and Functionalized Nanographene Oxide Incorporated Faster Dissolving Megestrol Acetate.Molecules (Basel, Switzerland) · 2021Article
- Fabrication of Carbamazepine Cocrystals: Characterization,BioMed research international · 2021Article
- Drug-Nutraceutical Co-Crystal and Salts for Making New and Improved Bi-Functional Analgesics.Pharmaceutics · 2020Article
- Article
- Pharmaceutical Co-Crystallization: Regulatory Aspects, Design, Characterization, and Applications.Advanced pharmaceutical bulletin · 2020Review
- Application of 1-Hydroxy-4,5-Dimethyl-Imidazole 3-Oxide as Coformer in Formation of Pharmaceutical Cocrystals.Pharmaceutics · 2020Article
- Mechanochemical Synthesis and Physicochemical Characterization of Isoniazid and Pyrazinamide Co-crystals With Glutaric Acid.Frontiers in chemistry · 2020Article
- Crystal engineering of exemestane to obtain a co-crystal with enhanced urease inhibition activity.IUCrJ · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cocrystal is a concept of the supramolecular chemistry which is gaining the extensive interest of researchers from pharmaceutical and chemical sciences and of drug regulatory agencies. The prominent reason of which is its ability to modify physicochemical properties of active pharmaceutical ingredients. During the development of the pharmaceutical product, formulators have to optimize the physicochemical properties of active pharmaceutical ingredients. Pharmaceutical cocrystals can be employed to improve vital physicochemical characteristics of a drug, including solubility, dissolution, bioavailability and stability of pharmaceutical compounds while maintaining its therapeutic activity. It is advantageous being a green synthesis approach for production of pharmaceutical compounds. The formation polymorphic forms, solvates, hydrates and salts of cocrystals during the synthesis reported in the literature which can be a potential issue in the development of pharmaceutical cocrystals. The approaches like hydrogen bonding rules, solubility parameters, screening through the CSD database or thermodynamic characteristics can be utilized for the rational design of cocrystals and selection of coformers for synthesis multi-component cocrystals. Considering the significance of pharmaceutical cocrystals pharmaceutical regulatory authorities in the United States and Europe issued guidance documents which may be helpful for pharmaceutical product registration in these regions. In this article, we deal with the design, synthesis, strategic aspects and characteristics of cocrystals along perspectives on its regulatory and intellectual property considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.